iNOS - Another cardiac target of calcineurin

Cardiovascular Research

Volumn 71, Issue 4, 2006, Pages 612-614

  Heger, Jacqueline ^a   Euler, Gerhild ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; INDUCIBLE NITRIC OXIDE SYNTHASE; TRANSCRIPTION FACTOR NFAT;

EDITORIAL; HEART HYPERTROPHY; HEART PROTECTION; ISCHEMIC PRECONDITIONING; MUSCLE DEVELOPMENT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ANIMALS; CALCINEURIN; ENZYME ACTIVATION; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIUM; NFATC TRANSCRIPTION FACTORS; NITRIC OXIDE SYNTHASE TYPE II; SIGNAL TRANSDUCTION;

EID: 33751577204     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.07.007     Document Type: Editorial

References (23)

1. Klee C.B., Crouch T.H., and Krinks M.H. Calcineurin: a calcium- and calmodulin-binding protein of the nervous system. Proc Natl Acad Sci U S A 76 (1979) 6270-6273
2. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93 (1998) 215-228
3. Obasanji-Blackshire K., Mesquita R., Molkentin J.D., Hart S.L., Marber M.S., Xia Y., et al. Calcineurin regulates NFAT-dependent iNOS expression and protection of cardiomyocytes: co-operation with Src tyrosine kinase. Cardiovasc Res 71 (2006) 672-683
4. Wilkins B.J., Dai Y.S., Bueno O.F., Parsons S.A., Xu J., Plank D.M., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94 (2004) 110-118
5. Parsons S.A., Millay D.P., Wilkins B.J., Bueno O.F., Tsika G.L., and Neilson J.R. Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy. J Biol Chem 279 (2004) 26192-26200
6. Anwar A., Taimor G., Korkususz H., Schreckenberg R., Berndt T., Abdallah Y., et al. PKC-independent signal transduction pathways increase SERCA2 expression in adult rat cardiomyocytes. J Mol Cell Cardiol 39 (2005) 911-919
7. Lim H.W., De Windt L.J., Steinberg L., Taigen T., Witt S.A., Kimball T.R., et al. Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation 101 (2000) 2431-2437
8. Hill J.A., Karimi M., Kutschke W., Davisson R.L., Zimmerman K., Wang Z., et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101 (2000) 2863-2869
9. Ding B., Price R.L., Borg T.K., Weinberg E.O., Halloran P.F., Lorell B.H., et al. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 84 (1999) 729-734
10. Pu W.T., Ma Q., and Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res 92 (2003) 725-731
11. Taimor G., Rakow A., and Piper H.M. Transcription activator protein 1 (AP-1) mediates NO-induced apoptosis of adult cardiomyocytes. FASEB J 15 (2001) 2518-2520
12. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33 (2001) 1897-1918
13. Kelly R.A., Balligand J.L., and Smith T.W. Nitric oxide and cardiac function. Circ Res 79 (1996) 363-380
14. Heger J., Gödecke A., Flögel U., Merx M.W., Molojavyi A., Kühn-Velten W.N., et al. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res 90 (2002) 93-99
15. Gödecke A., Molojavyi A., Heger J., Flogel U., Ding Z., Jacoby C., et al. Myoglobin protects the heart from inducible nitric-oxide synthase (iNOS)-mediated nitrosative stress. J Biol Chem 278 (2003) 21761-21776
16. Xi L., Jarrett N.C., Hess M.L., and Kukreja R.C. Myocardial ischemia/reperfusion injury in the inducible nitric oxide synthase knockout mice. Life Sci 65 (1999) 935-945
17. Li Q., Guo Y., Xuan Y.T., Lowenstein C.J., Stevenson S.C., Prabhu S.D., et al. Gene therapy with inducible nitric oxide synthase protects against myocardial infarction via a cyclooxygenase-2-dependent mechanism. Circ Res 92 (2003) 741-748
18. Li Q., Guo Y., Tan W., Stein A.B., Dawn B., Wu W.J., et al. Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol 290 (2006) H584-H589
19. Jones S.P., and Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40 (2006) 16-23
20. Wildhirt S.M., Weismueller S., Schulze C., Conrad N., Kornberg A., and Reichart B. Inducible nitric oxide synthase activation after ischemia/reperfusion contributes to myocardial dysfunction and extent of infarct size in rabbits: evidence for a late phase of nitric oxide-mediated reperfusion injury. Cardiovasc Res 43 (1999) 698-711
21. Dawn B., and Bolli R. Role of nitric oxide in myocardial preconditioning. Ann N Y Acad Sci 962 (2002) 18-41
22. Kim Y., Moon J.S., Lee K.S., Park S.Y., Cheong J., Kang H.S., et al. Ca2+/calmodulin-dependent protein phosphatase calcineurin mediates the expression of iNOS through IKK and NF-kappaB activity in LPS-stimulated mouse peritoneal macrophages and RAW 264.7 cells. Biochem Biophys Res Commun 314 (2004) 695-703
23. Li J., Song L., Zhang D., Wei L., and Huang C. Knockdown of NFAT3 blocked TPA-induced COX-2 and iNOS expression, and enhanced cell transformation in Cl41 cells. J Cell Biochem (2006) 10.1002/jcb.20834 [Electronic publication ahead of print]